Dr. David Porter, MD
Claim this profileUniversity of Pennsylvania
Studies Acute Myeloid Leukemia
Studies Myeloid Leukemia
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials David Porter, MD is currently running
DSG3-CAART Cell Therapy
for Pemphigus Vulgaris
This trial is testing new cell therapies for patients with pemphigus vulgaris who don't respond to standard treatments. The therapies involve modifying the patient's own immune cells to better fight the disease and potentially provide long-term relief.
Recruiting1 award Phase 14 criteria
Modified Stem Cell Transplant + CAR T Cells
for Acute Myeloid Leukemia
The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack your AML cells. The first treatment is a modified stem cell transplant, using blood-forming stem cells donated from a healthy donor. From the same donor, we will also make CAR T-cells, which are leukemia fighting cells, which will be given to the patient via an infusion into the vein after the transplanted stem cells have started to grow healthy blood cells. The modification of the stem cell transplant means that the healthy bone marrow cells will be "invisible" to the CAR T-cells that are trying to kill the leukemia cells.
Recruiting1 award Phase 1
More about David Porter, MD
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David Porter, MD has experience with
- CART-33
- CD33KO-HSPC
- Natalizumab
- Steroids
- DSG3-CAART
- Tadekinig Alfa (IL-18BP)
Breakdown of trials David Porter, MD has run
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Acute Graft-versus-Host Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Porter, MD specialize in?
David Porter, MD focuses on Acute Myeloid Leukemia and Myeloid Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved treating patients, or patients who are undergoing treatment.
Is David Porter, MD currently recruiting for clinical trials?
Yes, David Porter, MD is currently recruiting for 3 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that David Porter, MD has studied deeply?
Yes, David Porter, MD has studied treatments such as CART-33, CD33KO-HSPC, Natalizumab.
What is the best way to schedule an appointment with David Porter, MD?
Apply for one of the trials that David Porter, MD is conducting.
What is the office address of David Porter, MD?
The office of David Porter, MD is located at: University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the University of Pennsylvania.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.